Drugs / Norketotifen
Norketotifen
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03712163 | Oct 2018 → Feb 2019 | — | Emergo Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04610047 | Dec 2020 → Jan 2022 | influenza | Emergo Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04043923 | Oct 2019 → Apr 2020 | influenza | Emergo Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03887026 | Apr → May 2019 | allergic rhinitis | Emergo Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Norketotifen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03712163 ↗ |
| Known as | N-desmethylketotifen | ChEMBL registry synonym — accepted as the source's own label CHEMBL1197564 ↗ |
| Known as | NKT | “orally administered Norketotifen (NKT) in healthy subjects.” NCT03712163 ↗ |
| Modality | Small molecule | — CHEMBL1197564 ↗ |
| Route | Oral | “orally administered Norketotifen (NKT)” NCT03712163 ↗ |